Chronic fatigue syndrome: Current concepts of pathogenesis and treatment

Current Clinical Topics in Infectious Diseases

Volumn , Issue 19, 1999, Pages 135-159

  Lloyd, Andrew R ^a   Hickie, Ian ^a   Peterson, Phillip K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC FATIGUE SYNDROME; COMMUNICABLE DISEASE; DEPRESSION; FATIGUE; HUMAN; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; REVIEW;

COMMUNICABLE DISEASES; DEPRESSIVE DISORDER; FATIGUE; FATIGUE SYNDROME, CHRONIC; HUMANS; SICK ROLE;

EID: 0032601776     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (164)

1. Bennett BK, Hickie IB, Vollmer-Conna US, et al. The relationship between fatigue, psychological and immunological variables in acute infectious illness. Aust NZ J Psych 1998;32:180-186.
2. Hart B. Biological basis of the behaviour of sick animals. Neurosci Biobehav Rev 1988;12: 123-137.
3. Kent S, Bluthe R, Kelley KW, Dantzer R. Sickness behaviour as a new target for drug development. Trends Pharmacol Sci 1992;13: 24-28.
4. David A, Pelosi A, McDonald E, et al. Tired, weak or in need of rest: fatigue among general practice attenders. Br Med J 1990;301:1199-1202.
5. Lewis S, Wessely S. The epidemiology of fatigue: more questions than answers. J Epidemiol Community Health 1991;46:92-97.
6. Katon W, Walker EA. The relationship of chronic fatigue to psychiatric illness in community, primary care and tertiary care samples. In: Kleinman A, Straus S, eds. Chronic fatigue syndrome. Ciba Foundation Symposium 173. Chichester: John Wiley and Sons, 1993:193-204.
7. Wessely S, Hotopf M, Sharpe M. Physical mechanisms of fatigue. In: Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1998:39-80.
8. Wessely S, Hotopf M, Sharpe M. Fatigue and emotional disorders. In: Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1998:81-95.
9. White PD, Thomas JM, Amess J, Grover S, Kangro H, Clare A. The existence of a fatigue syndrome after glandular fever. Psychol Med 1995;25:907-916.
10. Fukuda K, Straus SE, Hickie I, et al. Chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-959.
11. Lloyd A, Hickie I, Boughton CR, Spencer O, Wakefield D. The prevalence of chronic fatigue syndrome in an Australian population. Med J Aust 1990;153:522.
12. Jason LA, Taylor R, Wagner L, et al. Estimating rates of chronic fatigue syndrome from a community-based sample: a pilot study. Am J Community Psychol 1995;23: 557- 568.
13. Lawrie SM, Manders DN, Geddes JR, Pelosi AJ. A population-based incidence study of chronic fatigue. Psychol Med 1997;27:343- 353.
14. Buchwald D, Umali P, Umali J, et al. Chronic fatigue and chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Ann Intern Med 1995;123:81.
15. McDonald E, David AS, Pelosi AJ, Mann AH. Chronic fatigue in primary care attenders. Psycholol Med 1993;23:987-998.
16. Hickie IB, Hooker AW, Hadzi-Pavlovic D, Bennett BK, Wilson AJ, Lloyd AR. Fatigue in selected primary care settings; sociodemographic and psychiatric correlates. Med J Aust 1996;164:585-588.
17. Wessley S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primay care study. Am J Public Health 1997;87:1449-1455.
18. Lloyd AR. Chronic fatigue and chronic fatigue syndrome: shifting boundaries and attributions. Am J Med 1998;105:75-105.
19. Straus SE. Studies of herpesvirus infection in chronic fatigue syndrome. In: Kleinman A, Straus S, eds. Chronic fatigue syndrome. Ciba Foundation Symposium 173. Chichester: John Wiley and Sons, 1993:132-139.
20. Behan PO, Behan WMH, Gow JW, Cavanagh H, Gillespie S. Enteroviruses and postviral fatigue syndrome. In: Kleinman A, Straus S, eds. Chronic fatigue syndrome. Ciba Foundation Symposium 173. Chichester: John Wiley and Sons, 1993:146-152.
21. Folkes T, Heneine W, Khan A, Chapman L, Schonberger L. Investigation of retroviral involvement in chronic fatigue syndrome. In: Kleinman A, Straus S, eds. Chronic fatigue syndrome. Ciba Foundation Symposium 173. Chichester: John Wiley and Sons, 1993: 160-166.
22. Lloyd AR, Wakefield D, Hickie I. Immunity and the pathophysiology of chronic fatigue syndrome. In: Kleinman A, Straus S, eds. Chronic fatigue syndrome. Ciba Foundation Symposium 173. Chichester: John Wiley and Sons, 1993:176-187.
23. Wessely S, Hotopf M, Sharpe M. CFS: viruses and immunity. In: Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1998:165-208.
24. Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224-1234.
25. McGregor NR, Dunstan RH, Zerbes M, Butt HL, Roberts TK, Klineberg IJ. Preliminary determination of a molecular basis to chronic fatigue syndrome. Biochem Mol Med 1996;57:73-80.
26. Wessely S, Hotopf M, Sharpe M. CFS and psychiatric disorder. In: Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1998:209-238.
27. Manningham R. The symptoms, nature and causes of the febricula or little fever: commonly called nervous or hysteric fever; the fever on the spirits; vapours, hypo or spleen, 2nd ed. London: J. Robinson, 1750.
28. Beard G. Neurasthenia, or nervous exhaustion. Boston Med Surg J 1869;3:217-221.
29. Cobb I. A manual of neurasthenia (nervous exhaustion). London: Balliere, Tindall and Cox, 1920.
30. Shorter E. Chronic fatigue syndrome in historical perspective. In: Kleinman A, Straus S, eds. Chronic fatigue syndrome. Ciba Foundation Symposium 173. Chichester: John Wiley and Sons, 1993:6-12.
31. Wessely S. The history of chronic fatigue syndrome. In: Straus SE, ed. Chronic fatigue syndrome. New York: Marcel Dekker, 1994:3-44.
32. Evans AC. Chronic brucellosis. JAMA 1934;103:665.
33. Isaacs R. Chronic infectious mononucleosis. Blood 1948;3:858-861.
34. Spink WW. What is chronic brucellosis? Ann Intern Med 1951;35:358-374.
35. Imboden JB, Cantor A, Cluff LE. Convalescence from influenza. A study of the psychological and clinical determinants. Arch Intern Med 1961;108:393-398.
36. Medical Staff of the Royal Free Hospital. An outbreak of encephalomyelitis in the Royal Free Hospital Group, London, 1955. Br Med J 1957;2:569-595.
37. McEvedy C, Beard A. Royal Free epidemic of 1955: a reconsideration. Br Med J 1970;1: 7-11.
38. White PD, Grover SA, Kangro HO, et al. The validity and reliability of the fatigue syndrome which follows glandular fever. Psychol Med 1995;25:917.
39. Wessely S, Chalder T, Hirsch S, et al. Postinfectious fatigue: prospective cohort study in primary care. Lancet 1995;345:1333.
40. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988;108: 387.
41. Sharpe MC, Archard LC, Banatvala JE, et al. A report-chronic fatigue: guidelines for research. J R Soc Med 1991;84:118.
42. Schluederberg A, Straus SE, Peterson P, et al. NIH conference. Chronic fatigue syndrome research. Definition and medical outcome assessment. Ann Intern Med 1992;117:325.
43. Hickie I, Lloyd A, Hadzi-Pavlovic D, et al. Can the chronic fatigue syndrome be defined by distinct clinical features? Psychological Med 1995;25:925.
44. Wessely S, Hotopf M, Sharpe M. The neurobiology of CFS. In: Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1998:239-265.
45. Cox B, Baxter M, Buckle A. The health and lifestyle survey. London: Health Promotion Research Trust, 1987.
46. Hotopf MH, Wessely S. Viruses, neurosis and fatigue. J Psychosom Res 1994;38:499-501.
47. Tobi M, Morag A, Ravid Z, et al. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet 1982;1:61.
48. Yousef GE, Bell EJ, Mann GF, et al. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet 1988;1: 146-150.
49. Josephs SF, Henry B, Balanchandran N, et al. HHV-6 reactivation in chronic fatigue syndrome. Lancet 1991;337:1346-1347.
50. Defreitas E, Hilliard B, Cheney PR, et al. Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci 1991;88:2922-2926.
51. Henle W, Henle GE, Horwitz CA. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Human Path 1974;5: 551-565.
52. Horwitz CA, Henle W, Henle G, Sehmitz H. Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the EpsteinBarr virus-induced early antigen complex. Am J Med 1975;58:330-338.
53. Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985;102:7-16.
54. Jones JF, Ray CG, Minnich LL, et al. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated early antigen antibodies. Ann Intern Med 1985;102:1-7.
55. Horwitz CA, Henle W, Henle G, Rudnick H, Latts E. Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. J Infect Dis 1985;151:1150-1153.
56. Gold D, Bowden R, Sixbey J, et al. Chronic fatigue. A prospective clinical and virologic study. JAMA 1990;264:48-53.
57. Sumaya C. Serologic and virologic epidemiology of Epstein-Barr virus: relevance to chronic fatigue syndrome. Rev Infect Dis 1990;13(suppl 1):S19-S25.
58. Gilliam A. Epidemiological study of an epidemic diagnosed as poliomyelitis occurring among the personnel of the Los Angeles Country General Hospital during the summer of 1934. Public Health Bulletin No. 240. Washington, DC: United States Public Health Service, Government Printing Office, 1938.
59. Sigurdsson B, Sigurjonsson J, Sigurdsson JHJ, Thorkelsson J, Gudmundsson KG. A disease epidemic in Iceland simulating poliomyelitis. Am J Hygiene 1950;52:222.
60. Pellew R. A clinical description of a disease resembling poliomyelitis seen in Adelaide 1949-51. Med J Aust 1951;1:944.
61. Fegan KG, Behan PO, Bell EJ. Myalgic encephalomyelitis-report of an epidemic. J Roy Coll Gen Pract 1983;33:335-337.
62. Keighley BD, Bell EJ. Sporadic myalgic encephalomyelitis in a rural practice. J Roy Coll Gen Pract 1983;33:339-341.
63. Calder B, Warnock P, McCartney R, Bell E. Coxsackie B viruses and the post-viral syndrome: a prospective study in general practice. J Roy Coll Gen Pract 1987;37:11-14.
64. Miller NA, Carmichael HA, Calder BD, et al. Antibody to Coxsackie B virus in diagnosing postviral fatigue syndrome. Br Med J 1991;302:140-143.
65. Halpin D, Wessely S. VP-1 antigen in chronic fatigue syndrome. Lancet 1989;1: 1028.
66. Lynch S, Seth R. Postviral fatigue syndrome and the VP-1 antigen. Lancet 1989;2:160.
67. Mawle A, Nisenbaum R, Dobbins J, et al. Seroepidemiology of chronic fatigue syndrome: a case control study. Clin Infect Dis 1995;21:1386-1389.
68. Swanink C, Melchers W, van der Meer J, et al. Enteroviruses and the chronic fatigue syndrome. Clin Infect Dis 1994;19:860-864.
69. Archard LC, Bowles NE, Behan PO, Bell EJ, Doyle D. Postviral fatigue syndrome: persistence of enterovirus RNA in muscle and elevated creatine kinase. J R Soc Med 1988;81:326-329.
70. Gow JW, Behan WMH, Clements GB, et al. Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome. Br Med J 1991;302:692-696.
71. Gow J, Behan P, Simpson K, McGarry F, Keir S, Behan P. Studies of enteroviruses in patients with chronic fatigue syndrome. Clin Infect Dis 199-4;18(suppl 1):S126-S129.
72. McArdle A, McArdle F, Jackson M, Page S, Fahal I, Edwards R. Investigation by polymerase chain reaction of enteroviral infection in patients with chronic fatigue syndrome. Clin Sci 1996;90:295-300.
73. Lindh G, Samuelson A, Hedlund I, Evengard B, Lindquist L, Ehmst A. No findings of enterovirus in Swedish patients with chronic fatigue syndrome. Scand J Infect Dis 1996;28:305-308.
74. Lloyd AR, Hales JP, Gandevia SC. Muscle strength, endurance and recovery in the post-infection fatigue syndrome. J Neurol Neurosurg Psychiatry 1988;51:1316-1322.
75. Lloyd AR, Gandevia SC, Hales JP. Muscle endurance, twitch properties, voluntary activation and perceived exertion in normal subjects and patients with chronic fatigue syndrome. Brain 1991;114:85-98.
76. Rutherford O, White P. Human quadriceps strength and fatiguability in patients with post-viral fatigue. J Neurol Neurosurg Psychiatry 1991;54:961-964.
77. Gibson H, Carroll N, Clague JE, Edwards RH. Exercise performance and fatiguability in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1993;156:993-998.
78. Lloyd AR. Muscle versus brain: chronic fatigue syndrome. Med J Aust 1990;153:530-534.
79. Holmes GP, Kaplan JE, Stewart JA, et al. A cluster of patients with a chronic mononuclcosis-like syndrome. JAMA 1987;257:2297-2302.
80. Levine PH, Jacobsen S, Pocinki AG, et al. Viral, epidemiologic and virologic studies in four clusters of the chronic fatigue syndrome. Arch Intern Med 1992;152:1611-1616.
81. Buchwald D, Cheney PR, Peterson DL, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992; 116:103-113.
82. Yalcin S, Kuratsune H, Yamaguchi K, Kitani T, Yamanishi K. Prevalence of human herpesvirus 6 variants A and B in patients with chronic fatigue syndrome. Microbiol Immunol 1994;38:587-590.
83. Di Luca D, Zorzenon M, Mirandola P, et al. Human herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. J Clin Microbiol 1995;33:1660-1661.
84. Hay J, Jenkins FJ. Human herpesviruses and chronic fatigue syndrome. In: Straus SE, ed. Chronic fatigue syndrome. New York: Marcel Dekker, 1994:181-198.
85. Khan AS, Heneine WM, Chapman LE, et al. Assessment of a retrovirus sequence and other possible risk factors for the chronic fatigue syndrome in adults. Ann Intern Med 1993;118:241-245.
86. Gow JW, Simpson K, Schlicphake A, et al. Search for a retrovirus in the chronic fatigue syndrome. J Clin Pathol 1992;45:1058-1061.
87. Heneine W, Woods TC, Sinha SD, et al. Lack of evidence for infection with known human and animal retroviruses in patients with chronic fatigue syndrome. Clin Infect Dis 1994;18(suppl 1):S121-S125.
88. Flugel RM, Mahnke C, Geiger A, Komaroff AL. Absence of antibody to human spumaretrovirus in patients with chronic fatigue syndrome. Clin Infect Dis 1992;14: 623-624.
89. Lloyd A, Wakefield D, Dwyer J, Boughton C. What is myalgic encephalomyelitis? Lancet 1988;1:1286-1287.
90. Marmion BP, Shannon M, Maddocks I, Storm P, Penttila I. Protracted debility and fatigue after acute Q fever. Lancet 1996;347: 977-978.
91. Dinarello CA. Interleukin-1. Rev Infect Dis 1984;6:51-95.
92. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumor necrosis factor. Lancet 1989;1:1122-1125.
93. Van Snick J. Interleukin-6: an overview. Ann Rev Immunol 1990;8:253-289.
94. Wakefield D, Lloyd AR. The pathophysiology of myalgic encephalomyelitis. Lancet. 1987;2:918-919.
95. Strober W. Immunological function in chronic fatigue syndrome. In: Straus SE, ed. Chronic fatigue syndrome. New York: Marcel Dekker, 1994:207-240.
96. Lloyd AR, Wakefield D, Dwyer J, Boughton C. Immunological abnormalities in the chronic fatigue syndrome. Med J Aust 1989;151:122-124.
97. Lloyd A, Hickie I, Hickie C, Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992;87:76-79.
98. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990;28:1403-1410.
99. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue. Clin Infect Dis 1994;18(suppl 1):S136-S41.
100. Tirelli U, Marotta G, Improta S, Pinto A. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994;40:601-608.
101. Swanink CMA, Vereoulen JHMM, Galama JMD, et al. Lymphocyte subsets, apoptosis and eytokines in patients with chronic fatigue syndrome. J Infect Dis 1996;173:460-463.
102. Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991;338:707-712.
103. Mawle AC, Nisenbaum R, Dobbins JG, et al. Immune responses associated with chronic fatigue syndrome: a case-control study. J Infect Dis 1997;175:136-141.
104. Wakefield D, Lloyd A, Brockman A. Immunoglobulin subclass abnormalities in patients with chronic fatigue syndrome. Pediatr Infect Dis J 1990;9(suppl 1):S50-S53.
105. Komaroff A, Geiger A, Wormsley S. IgG sub-class deficiencies in aptients with chronic fatigue syndrome. Lancet 1988;1:1288-1289.
106. Bennett AL, Fagioli LR, Schur PH, et al. Immunoglobulin subclass levels in chronic fatigue syndrome. J Clin Immunol 1996;16:315-320.
107. Abbott RJ, Bolderson I, Gruer PJK. IFN-γ and IFN-α in CSF in viral meningitis. Lancet 1985;2:456-457.
108. Ho-Yen DO, Carrington D. Alpha-interferon in cerebrospinal fluid of patients with suspected meningitis. J Clin Pathol 1987;40: 83-86.
109. Lebon P, Boutin B, Dulac O, Ponsot G, Arthuis M. Interferon γ in acute and subacute encephalitis. Br Med J 1988;296:9-11.
110. Straus SE, Dale JK, Peter JB, Dinarello CA. Circulating Iymphokine levels in the chronic fatigue syndrome. J Infect Dis 1989;160: 1085-1086.
111. Lloyd A, Hickie I, Brockman A, Dwyer J, Wakefield D. Serum and cerebrospinal fluid eytokine levels in patients with chronic fatigue syndrome and control subjects. J Infect Dis 1991;164:1023.
112. Linde A, Andersson B, Svenson SB, et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 1992;165:994-1000.
113. Chao CC, Janoff EN, Hu S, et al. Altered eytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991;3: 292-298.
114. Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, Wolff SM, Komaroff AL. Interleukin-1β, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 1997;17:253-261.
115. Lloyd A, Gandevia S, Brockman A, Hales J, Wakefield D. Cytokine production and fatigue in patients and healthy controls in response to exercise. Clin Infect Dis 1994;18(suppl 1):S142-S146.
116. Chao CC, Delahunt M, Hu S, Close K, Petersen PK. Immunologically-mediated fatigue: a murine model. Clin Immunol Immunopathol 1992;64:161-164.
117. Lloyd AR, Wakefield D, Hickie I. Immunity and the pathopbysiology of chronic fatigue syndrome. In: Kleinman A, Straus S, eds. Chronic fatigue syndrome. Chichester: Wiley, 1993:176-187.
118. Taerk GS, Toner BB, Salit IE, et al. Depression in patients with neuromyasthenia (benign myalgic encephalomyelitis). Int J Psychiatry Med 1987;17:49-56.
119. Kruesi MJP, Dale J, Straus SE. Psychiatric diagnoses in patients who have chronic fatigue syndrome. J Clin Psychiatry 1989; 50:53-56.
120. Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with chronic fatigue syndrome. Br J Psychiatry 1990; 156: 534-540.
121. Wessely S, Powell R. Fatigue syndromes: a comparison of chronic "postviral" fatigue with neuromuscular and affective disorders. J Neurol Neurosurg Psychiatry 1989;52:940-948.
122. Clark MR, Katon WJ. The relevance of psychiatric research on somatization to the concept of chronic fatigue syndrome. In: Straus S, ed. Chronic fatigue syndrome. New York: Marcel Dekker, 1994:329-349.
123. Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224-1234.
124. Moldofsky H. Fibromyalgia, sleep disorder and chronic syndrome. In: Kleinman A, Straus S, eds. Chronic fatigue syndrome. Ciba Foundation Symposium 173. Chichester: John Wiley and Sons, 1993:262-279.
125. Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995;274:961-967.
126. Beam J, Allain A, Coskeran P, et al. Neuroendocrine responses to d-fenfluramine and insulin-hypoglycaemia in chronic fatigue syndrome. Biol Psychiat 1995;37:245-252.
127. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbances in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975;37:341-351.
128. Morriss R, Sharpe M, Sharpley AL, Cowen PJ, Hawton K, Morris J. Abnormalities of sleep in patients with chronic fatigue syndrome. Br Med J 1993;306:1161-1164.
129. Ambrogetti A, Olson L. Consideration of narcolepsy in the differential diagnosis of chronic fatigue syndrome. Med J Aust 1994;160:426-429.
130. Wilson A, Hickie I, Lloyd A, et al. Longitudinal study of outcome of chronic fatigue syndrome. Br Med J 1994;308:756-759.
131. Nelson E, Kirk H, McHugo G. Chief complaint fatigue: a longitudinal study from the patient's perspective. Family Practice Res J 1987;6:175-188.
132. Teitelbaum J, Bird B. Effective treatment of severe chronic fatigue: a report of a series of 64 patients. J Musculoskeletal Pain 1995;3: 91-110.
133. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. Quart J Med 1997;90:223-233.
134. Wilson A, Hickie I, Lloyd A, Wakefield D. The treatment of chronic fatigue syndrome: science and speculation. Am J Med 1994;96: 544-550.
135. Hickie I, Lloyd A, Wakefield D. Chronic fatigue syndrome: current perspectives on evaluation and management. Med J Aust 1995;163:314-318.
136. Sackett D, ed. Cochrane collaboration. Br Med J 1994;309:1514-1515.
137. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebocontrolled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990;89:561-568.
138. Peterson PK, Shepard J, Macres M, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990;89:554-560.
139. Rowe KS. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. J Psychiatr Res 1997:133-147.
140. Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med 1997;103:38-43.
141. McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, Garcia-Borregvero D, Blackwelder W, Straits SE. Low-dose hydrocordisone for treatment of chronic fatigue syndrome: a randomized, controlled trial. JAMA 1998;280:1061-1066.
142. Peterson PK, Pheley A, Schroeppel J, et al. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med 1998;158: 908-914.
143. Straus SE, Dale JK, Tobi M, Lawley T, Preble O, Blaese M, Hallahan C, Henle W. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial. N Engl J Med 1988;319: 1692-1698.
144. Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94:197-203.
145. See DM, Tilles JG. Alpha interferon treatment of patients with chronic fatigue syndrome. Immunol Invest 1996;25:153-164.
146. 12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18(suppl 1):S88-S95.
147. Vercoulen JHMM, Swanink CMA, Zitman FG, et al. Randomised, double-blind, placebo-controlled study of fiuoxetine in chronic fatigue syndrome. Lancet 1996;347: 858-861.
148. Hickie I, Wilson AJ, Wright JM, Bennett BK, Wakefield D, Lloyd A. A randomised, double-blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. Br J Psychiatry 1998 (in press).
149. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986;29: 1371-1377.
150. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991;18:447-451.
151. Natelson BH, Cheu J, Pareja J, Ellis SP, Policastro T, Findley TW. Randomized, double-blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology 1996; 124:226-230.
152. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Biol Psychiatry 1997;35:16-23.
153. Snorrason E, Geirsson A, Stefansson K. Trial of a selective acetylcholinesterase inhibitor, galantliamine hydrobromide, in the treatment of chronic fatigue syndrome. J Chronic Fatigue Syndrome 1996;2:35-54.
154. Butler S, Chalder T, Ron M, Wessely S. Cognitive behaviour therapy in the chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1991;54:153-158.
155. Deale A, Chalder T, Marks I, Wessely S. Cognitive behaviour therapy for chronic fatigue syndrome: a randomised controlled trial. Am J Psychiatry 1997;154:408-414.
156. Friedberg F, Krupp LB. A comparison of cognitive behavioural treatment for chronic fatigue syndrome and primary depression. Clin Infect Dis 1994;18(suppl 1):S105-S110.
157. Sharpe M, Hawton K, Simkin S, et al. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomised controlled trial. Br Med J 1996;312:22-26.
158. Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. Br Med J 1997;314:1647-1652.
159. Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs. placebo for chronic fatigue syndrome. Arch Intern Med 1989;149:2501-2503.
160. Steinberg P, McNutt BE, Marshall P, et al. Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. J Allergy Clin Immunol 1996;97:119-126.
161. Behan PO, Behan WMH, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 1990;82:209-216.
162. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic faligue syndrome. Lancet 1991;337:757-760.
163. Wessely S, Hotopf M, Sharpe M. Treatment of the patient with CFS. In: Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1998:381-398.
164. Wessely S, Hotopf M, Sharpe M. The neurobiology of CFS. In: Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1998:239-265.